Significance of selectively targeted apoptotic rete cells in graft-versus-host disease

被引:15
作者
Murphy, GF
Korngold, R
机构
[1] Brigham & Womens Hosp, Eugene Braunwald Res Ctr 401, Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA
关键词
acute graft-versus host disease; hematopoietic stem cell transplantation; target cells; apoptosis;
D O I
10.1016/j.bbmt.2004.02.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Considerable data exist regarding the mechanisms of allostimulation and homing (the effector phases) in graft-versus-host disease (GVHD). Current dogma suggests that target specificity involves preferential injury to epithelial surfaces of the skin and squamous mucosae, liver, and gut. Little attention has been devoted, however, to mechanisms of cellular targeting or to whether heterogeneity exists in target tissues with regard to a threshold for cellular injury. A recent breakthrough in understanding the target stage of GVHD indicates that the predominant pathway of injury to squamous epithelial cells involves apoptosis. Moreover, apoptotic injury may be associated or unassociated with local T-cell infiltration and involves phenotypically and antigenically distinctive epithelial cells within the basal layer of the skin and squamous mucosa. These cells are confined to rete ridges in the skin and retelike prominences in the dorsal tongue and are designated as selectively targeted apoptotic rete (STAR) cells. The discovery of STAR cells in GVHD paves the way for speculation and experimentation to determine why these subpopulations are selectively vulnerable and how soluble and cellular effectors of apoptosis contribute to their ultimate demise. Novel approaches to GVHD treatment derived from understanding mechanisms of selective epithelial injury are likely to use strategies to render target cells less susceptible to the apoptosis that is ultimately responsible for organ dysfunction and failure. (C) 2004 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 89 条
[81]   Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma [J].
Verdonck, LF ;
Dekker, AW ;
Lokhorst, HM ;
Petersen, EJ ;
Nieuwenhuis, HK .
BLOOD, 1997, 90 (10) :4201-4205
[82]  
WAGNER JL, IN PRESS GRAFT VS HO
[83]   HUMAN DERMAL MAST-CELLS CONTAIN AND RELEASE TUMOR-NECROSIS-FACTOR-ALPHA, WHICH INDUCES ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 [J].
WALSH, LJ ;
TRINCHIERI, G ;
WALDORF, HA ;
WHITAKER, D ;
MURPHY, GF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4220-4224
[84]   Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes [J].
Weisdorf, D ;
Bishop, M ;
Dharan, B ;
Bolwell, B ;
Cahn, JY ;
Cairo, M ;
Giralt, S ;
Klein, J ;
Lazarus, H ;
Litzow, M ;
Marks, D ;
McCarthy, P ;
Miller, C ;
Milone, G ;
Russell, J ;
Schultz, KR ;
Sierra, J ;
Wiernik, P ;
Keating, A ;
Loberiza, F ;
Kollman, C ;
Horowitz, M .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (04) :213-220
[85]   An epithelial target site in experimental graftversus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression [J].
Whitaker-Menezes, D ;
Jones, SC ;
Friedman, TM ;
Korngold, R ;
Murphy, GF .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) :559-570
[86]  
WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182
[87]   DEVELOPMENT OF BIOLOGICALLY-ACTIVE PEPTIDES BASED ON ANTIBODY STRUCTURE [J].
WILLIAMS, WV ;
MOSS, DA ;
KIEBEREMMONS, T ;
COHEN, JA ;
MYERS, JN ;
WEINER, DB ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (14) :5537-5541
[88]  
WOODRUFF JM, 1969, LAB INVEST, V20, P499
[89]   Apaf-1, a human protein homologous to C-elegans CED-4, participates in cytochrome c-dependent activation of caspase-3 [J].
Zou, H ;
Henzel, WJ ;
Liu, XS ;
Lutschg, A ;
Wang, XD .
CELL, 1997, 90 (03) :405-413